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In Brief
Seasonal cycles of food intake and energy expenditure arise from changes in deiodinase gene expression and thyroid hormone production in hypothalamic tanycytes. Using a monoclonal antibody antagonist of FGFR1c, Samms et al. demonstrate that signaling via FGF receptors occurs through a similar pathway in tanycytes to regulate energy balance.
SUMMARY
Hypothalamic tanycytes are considered to function as sensors of peripheral metabolism [1] . To facilitate this role, they express a wide range of receptors, including fibroblast growth factor receptor 1 (FGFR1). Using a monoclonal antibody (IMC-H7) that selectively antagonizes the FGFR1c isoform [2] , we investigated possible actions of FGFR1c in a natural animal model of adiposity, the Siberian hamster. Infusion of IMC-H7 into the third ventricle suppressed appetite and increased energy expenditure. Likewise, peripheral treatment with IMC-H7 decreased appetite and body weight and increased energy expenditure and fat oxidation. A greater reduction in body weight and caloric intake was observed in response to IMC-H7 during the long-day fat state as compared to the shortday lean state. This enhanced response to IMC-H7 was also observed in calorically restricted hamsters maintained in long days, suggesting that it is the central photoperiodic state rather than the peripheral adiposity that determines the response to FGFR1c antagonism. Hypothalamic thyroid hormone availability is controlled by deiodinase enzymes (DIO2 and DIO3) expressed in tanycytes and is the key regulator of seasonal cycles of energy balance [3, 4] . Therefore, we determined the effect of IMC-H7 on hypothalamic expression of these deiodinase enzymes. The reductions in food intake and body weight were always associated with decreased expression of DIO2 in the hypothalamic ependymal cell layer containing tanycytes. These data provide further support for the notion the tanycytes are an important component of the mechanism by which the hypothalamus integrates central and peripheral signals to regulate energy intake and expenditure.
RESULTS AND DISCUSSION

Expression of FGFR1c in Tanycytes
Mammals that have evolved in temperate and polar environments generally display profound seasonal cycles in energy balance comprising changes in appetite, energy expenditure, and fat deposition [5] . Analysis of hypothalamic function in seasonal mammals is a strategy to identify novel pharmacological targets for the treatment of obesity and its comorbidities [4, 6] . Recently, it has become clear that hypothalamic tanycytes play a pivotal role in generating seasonal cycles. Annual changes in photoperiod regulate many genes in the ependymal cell layer that contains the tanycyte cell soma, including nestin, GPR50, and those encoding processing enzymes and transporters for thyroid hormone and retinoic acid [7] [8] [9] . In situ hybridization revealed a high level of expression of FGFR1c in this cell layer ( Figures 1A and S1 ), consistent with previous qPCR studies in the mouse [10] . FGFR1c is a member of the tyrosine kinase FGF receptor family that is thought to play diverse roles in the development, growth, and regeneration of tissue [11] . Antibody-mediated targeting of FGFR1c reduces body weight, fat mass, and insulin resistance in animal models of obesity and type II diabetes [2, 12, 13] . The aim of the current studies was to investigate the role of FGFR1c in the regulation of body weight, food intake, and metabolism using a monoclonal antibody antagonist (IMC-H7) that selectively targets the FGFR1c isoform [2] .
Although IMC-H7 was shown to bind specifically in the mediobasal hypothalamus of mice [2] and was originally characterized as an antagonist on the basis of its ability to block binding of FGF2 to FGFR1c expressed in a myoblast cell line [2] , we confirmed its ability to target tanycytes by testing its activity in primary cultures [14] . Ligand-mediated activation of tyrosine kinase FGFR is characterized by induction of MAP kinase (ERK1/2) and Akt signaling, so we determined its ability to inhibit signaling of a canonical FGFR1 ligand, FGF2. FGF2 (10 nM) treatment increased the phosphorylation of ERK1/2 and Akt in rat primary tanycytes ( Figures 1B-1E ). IMC-H7 itself did not increase phosphorylation of ERK1/2 or Akt either acutely or after a 1 hr incubation period ( Figures 1B-1E) ; however, IMC-H7 was able to block FGF2-mediated phosphorylation of ERK1/2 and Akt when preincubated with the primary cell cultures for 1 hr prior to addition of FGF2 (Figures 1B-1E ). Our previous immunohistochemical and PCR analyses of the primary cultures derived from microdissected ependymal walls suggests that they are highly enriched for tanycyte markers (vimentin), but not for markers of astrocytes (GFAP) or neighboring pars tuberalis (TSHb) [14] . We therefore infer that IMC-H7 is exerting its antagonistic action via binding to receptors on tanycytes.
We determined the effect of FGFR1c blockade in vivo by infusing 0.5 mg IMC-H7 via an intracerebroventricular cannula. Such treatment caused a significant reduction in body weight that had not returned to baseline by 96 hr after treatment (Figure 1F ). This reflected a significant reduction in food intake over the first 48 hr after infusion ( Figure 1G ) that did not return to baseline until 72 hr after infusion. It also caused an increase in energy expenditure from 72-96 hr after infusion ( Figure 1H ) that was associated with a trend (p = 0.07) toward increased fat oxidation during the dark phase (Figure 1I ). Although fasting plasma leptin concentrations were not affected 96 hr after IMC-H7 administration ( Figure 1J ), insulin concentrations were decreased ( Figure 1K ).
Systemic FGFR1c Blockade Mimics Central Responses
Tanycytes form a structural component of the blood-brain barrier in that their end feet appose endothelial cells surrounding capillaries in the median eminence [15] . They express a wide range of hormone receptors and nutrient sensors that underpin their role in mediating metabolic signaling to the hypothalamus [16, 17] . The objective of this study was to compare peripheral effects of FGFR1c blockade to the central effects.
There was a dose-dependent decrease in body weight after systemic IMC-H7 treatment ( Figure 2A ). This persisted for the first 5-6 days after infusion in hamsters treated with the highest dose (3 mg/kg) of IMC-H7. This long-term action is consistent with the 3-5 day half-life of a similar monoclonal antibody antagonist, as previously estimated in mice [2] . The weight loss reflected a substantial suppression of food intake (Figure 2B ), but also an increase in energy expenditure in hamsters treated with the highest dose of IMC-H7, as assessed on days 6-7 after the start of treatment ( Figure 2C ). At this point, fat oxidation was significantly increased ( Figure 2D ), and carbohydrate oxidation decreased ( Figure 2E ). Analysis of body composition using computed tomography revealed that the loss of body weight induced by FGFR1c blockade reflected a significant reduction in the volume of adipose tissue ( Figures 2F and 2G) . 
Photoperiodic Regulation of Responses to FGFR1c Blockade
We repeated the dose-response study in hamsters acclimatized to short photoperiods (SD) for 12 weeks to induce a lean hypophagic state and noted that the responses to IMC-H7 were attenuated ( Figure S2 ). We therefore compared directly responses to IMC-H7 in age-matched hamsters previously exposed to long photoperiods (LD) or SD ( Figures 2H-2J and 3) . Treatment with IMC-H7 at a dose of 3 mg/kg decreased body weight in hamsters maintained in both photoperiods ( Figures 3A and 3B ), but again, the effects of IMC-H7 were more pronounced in hamsters maintained in their LD fat state: body weight was reduced by 12% in hamsters in LD compared to 7% reduction in hamsters maintained in SD ( Figures 3A and 3B) . Similarly, there were clear suppressive effects of IMC-H7 on food intake throughout the treatment period in hamsters maintained in LD ( Figure 3C ) and on days 2 and 3 in hamsters in SD (Figure 3D) . Treatment with IMC-H7 significantly increased daily energy expenditure in animals maintained in LD ( Figure 3E ). Importantly, similar to the pilot dose-response studies, treatment with IMC-H7 did not significantly affect energy expenditure in hamsters in SD ( Figure 3F ). Forty-eight hours after IMC-H7 treatment began, there was a clear switch in metabolic fuel utilization, that is, a significant increase in fat oxidation ( Figures 3G and 3H ) and a decrease in carbohydrate oxidation ( Figures 3I and 3J ). This occurred in hamsters treated with IMC-H7 maintained in both photoperiods, but again, the magnitudes of these responses were reduced in the SD-exposed hamsters (Figures 3G-3J) . Fasting blood glucose concentrations were not affected at the end of the study ( Figure 2H ), but fasting insulin ( Figure 2I ) and leptin (Figure 2J) concentrations were significantly lower in hamsters in LD. The insulin response mirrored that after intracerebroventricular administration of IMC-H7 ( Figure 1K ). Insulin concentrations were not significantly affected by FGFR1c antagonism Figure S3 for the effects of IMC-H7 in hamsters in LD previously food-restricted to reduce adiposity.
in hamsters in SD ( Figure 2I ), and circulating leptin concentrations were close to the limit of detection in all hamsters in SD, so no effect was detected (Figure 2J) . Clearly, systemic treatment with IMC-H7 has potent effects on food intake and body weight that resemble the effects of central treatment, so these observations are consistent with the view that peripheral treatment with IMC-H7 may also be targeting central FGFR1c. The suppression of appetite is consistent with a central action, and it is noticeable that the decrease in circulating leptin observed after systemic administration of IMC-H7 is not sufficient to promote a compensatory hyperphagic response.
We found no evidence of altered FGFR1c gene expression in the ependymal cell layer of hamsters in LD and SD ( Figure S1 ) that might explain the differential responses to FGFR1c antagonism. We considered that these differential responses to IMC-H7 in LD and SD could therefore either be due to the reduced peripheral adiposity of hamsters in the SD state (e.g., epididymal fat reduction of 20%) or could be a reflection of the underlying photoperiodically regulated central state. To distinguish these two possibilities, we tested the effects of IMC-H7 in hamsters in which peripheral fat loss was caused by caloric restriction for 5 weeks rather than by exposure to a SD photoperiod ( Figure S3 ). Clear catabolic responses to IMC-H7 were observed that resembled those previously observed in fat hamsters in LD ( Figure S3 ), suggesting that central photoperiodic state rather than peripheral adiposity was the key factor determining the response to FGFR1c blockade.
Hypothalamic Gene Expression after FGFR1c Blockade
To understand better how blockade of FGFR1c might affect tanycyte function, we used in situ hybridization to assess expression of DIO2 and DIO3 after IMC-H7 treatment. These genes are pivotal in the seasonal regulation of energy balance by virtue of their regulation of the local availability of tri-iodothyronine (T3) [18] . As previously reported, there was clear mRNA expression for both DIO2 and DIO3 in the ependymal layer surrounding the ventral third ventricle, and SD exposure reduced DIO2 mRNA expression by 3-fold but hugely increased DIO3 expression ( Figures 4A-4D) . Importantly, treatment of hamsters in LD with IMC-H7 resulted in a 2-fold decrease in DIO2 mRNA expression (p < 0.001) when compared to vehicle-treated hamsters ( Figures 4A and 4B ). There were no effects of treatment on DIO3 mRNA expression in animals maintained in either LD or SD (Figures 4A-4D ). This clear decrease in DIO2 expression in the ependymal cell layer was also observed in the study in which previously food-restricted hamsters in LD were treated with IMC-H7 ( Figures 4E and 4F) . The decrease in DIO2 expression would be expected to cause a reduction in local T3 availability in the surrounding hypothalamus [19] . We have previously observed that local delivery of T3 into the hypothalamus via slow-release microimplants causes increased food intake, reduced energy expenditure, and thus increased body weight in hamsters [20] , so the reverse responses observed after IMC-H7 treatment in the current study are consistent with the reduction in DIO2 expression and in T3 availability.
We also analyzed a number of other genes in the hypothalamus implicated in the control of food intake and energy expenditure. NPY, AgRP, POMC, and CART mRNA expression were highly localized to the arcuate nucleus (ARC) and TRH and CRH mRNA were highly expressed in the paraventricular nucleus, but there were no effects of photoperiod or IMC-H7 treatment on any of these known homeostatic regulators of energy balance ( Figures 4H and S4 ). There was a significant increase in somatostatin (SRIF) mRNA abundance in the ARC after IMC-H7 treatment, although the magnitude of increase was not as great as that induced by exposure to SD ( Figure S4 ). The SDinduced increase in SRIF has been observed previously in hamsters [21, 22] , and it is likely to contribute to the development of the SD phenotype [23] , so the increase in SRIF may be one of the downstream mediators of the catabolic response resulting from FGFR1c blockade. Collectively, these observations indicate that the effects of IMC-H7 on DIO2 expression are very specific to the ependymal cell layer, consistent with the view that FGFR1c signaling is specific to tanycytes. Given the previous evidence that photoperiod regulates deiodinase gene expression in tanycytes, we should view these cells as a locus that integrates both photoperiodic and other nutritional and metabolic signals to regulate energy balance.
Conclusions
Our observations in hamsters concur with previous studies in mice, rats, and rhesus monkeys that antibody-mediated inhibition of FGFR1c decreases food intake and body weight [2] and extend our understanding in two important directions. First, they provide evidence that the effects of IMC-H7 may be mediated centrally via regulation of tanycyte function. FGFR signaling in primary cultures of tanycytes was blocked by IMC-H7, and in vivo treatment with IMC-H7 significantly reduced DIO2 expression in the ependymal cell layer, whereas gene expression encoding homeostatic peptides (NPY, AgRP, POMC, and CART [24] ) was unaffected. It has been previously suggested that the effects of IMC-H7 on food intake are likely to be central on the grounds that a similar antibody (IMC-A1) bound to the median eminence/mediobasal hypothalamus in mice [2] . We found that ICV infusion of IMC-H7 directly into the hypothalamic third ventricle significantly decreased body weight at an approximately 200-fold lower dose than that required via peripheral administration, again consistent with a local site of action within the hypothalamus.
Second, we found that the effect of FGFR1c inhibition on caloric intake was greater in hamsters in the LD fat state when compared to those in the SD lean state, suggesting that activity of the FGFR1c system might vary as a function of either adiposity or photoperiod. One interpretation of these findings might be that adipose tissue is a direct target of IMC-H7, and thus fat hamsters in LD would show an enhanced response. White adipose tissue expresses FGFR1c, and targeted knockout of this receptor from adipocytes greatly reduces the responsiveness of mice to FGF21, a ligand for FGFR1c [25] . However, the effects of FGFR1c blockade in calorically restricted hamsters in LD whose fat stores had been depleted to levels characteristic of SD hamsters were comparable to those in hamsters in LD on ad libitum diet. This suggests that photoperiod, rather than peripheral adiposity, is the more important determinant of the effects of FGFR1c blockade, so it is changes in central state that determine the response to IMC-H7, that is, the primary actions of IMC-H7 are central rather than peripheral. This interpretation is reinforced by the striking effects of FGFR1c blockade on DIO2 gene expression in the hypothalamus, as changes in expression of hypothalamic deiodinases are a key mechanism underlying photoperiodic regulation of cycles of appetite and metabolism [4] . Although the predominant form of circulating thyroid hormone is the relatively inactive precursor thyroxine (T4), it is the tanycyte-specific expression of the MCT8 transporter and of deiodinase enzymes that regulate local bioactive T3 availability in the hypothalamus [26, 27] . The reduction in food intake that occurs when switching Siberian hamsters from LD to SD is primarily associated with the reduction in hypothalamic thyroid hormone availability resulting from decreased expression of DIO2 and a reciprocal increase in DIO3 expression in the ependymal tanycyte layer [7, 20] . In the current study, the IMC-H7-mediated reduction in daily food intake was associated with a significant decrease in DIO2 mRNA expression in the ependymal tanycyte layer when hamsters were housed in LD, but not in SD when DIO2 expression was already reduced. Likewise, there was a significant decrease in DIO2 mRNA expression in the ependymal tanycyte layer of the mediobasal hypothalamus in foodrestricted animals treated with IMC-H7 when compared to vehicle. Thus, antibody-mediated inhibition of food intake is associated with a reduction in DIO2 mRNA expression in the tanycyte layer of the mediobasal hypothalamus regardless of the prevailing adiposity. Furthermore, it seems that the blunted responses to IMC-H7 treatment in animals maintained in SD may be due to the already reduced mRNA expression of DIO2 in the mediobasal hypothalamus. The mechanism of action of thyroid hormone on appetite remains to be determined, but the increased expression of SRIF may be one potential pathway. There is also robust evidence in mice that fasting induces DIO2 expression and increases T3 concentrations in the mediobasal hypothalamus and that the glial elements expressing DIO2 are closely apposed to NPY/AgRP neurons in the ARC [28] . The increase in T3 was demonstrated to promote mitochondrial uncoupling and increase neuronal excitability in these orexigenic NPY/AgRP neurons via an uncoupling protein 2 mechanism [28] . Conversely, a decrease in DIO2 expression and therefore T3 availability might be expected to reduce NPY/AgRP activity, which would then contribute to the decreased food intake that we observed after FGFR1c blockade. Collectively, we consider that our in vitro and in vivo observations provide evidence that FGFR1c signaling in tanycytes and subsequent regulation of local thyroid hormone availability is a physiologically important mechanism in the regulation of appetite.
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